Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SynKIR 110

Drug Profile

SynKIR 110

Alternative Names: Anti-mesothelin killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapy - Verismo Therapeutics; KIR-CAR-meso - Verismo Therapeutics; SynKIR-meso; SynKIR-meso CAR-T cells; SynKIR™-110

Latest Information Update: 08 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verismo Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cholangiocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
  • Preclinical Pancreatic cancer; Solid tumours

Most Recent Events

  • 02 May 2023 Preclinical trials in Solid tumours in USA (Parenteral), prior to May 2023
  • 02 May 2023 Pharmacodynamics data from a preclinical trial in Solid tumour released by Verismo Therapeutics
  • 05 Apr 2023 SynKIR 110 receives Fast Track designation for Mesothelioma [IV,Infusion] (Late-stage disease, Second-line therapy or greater) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top